Medical Devices

A new study reveals the biggest planning mistake in enterprise IT is rigid strategy. For companies betting on digital transformation, adaptability is now survival.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

How a Swedish city's new aquatic center, powered by unique CO₂ technology, reveals a future where public infrastructure can be both sustainable and strategic.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

A strategic leadership shift at BoldAge PACE signals a major push to expand its home-based senior care model, aiming to transform how America ages.

A new industry-funded study in Rouyn-Noranda finds diet, not the Horne Smelter, is the main source of arsenic exposure, challenging years of health warnings.

Capsa Healthcare's acquisition of The Harloff Company isn't just another merger; it's a strategic play to build an end-to-end healthcare solutions empire.

A new FDA-cleared laser offers a drug-free option for millions with tennis elbow. But does the science justify the cost and will patients have access?

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

A new partnership is challenging the supplement status quo with a creatine product that targets brain energy, not just brawn, for a new era in women's health.

A top pet wellness brand is making lab results for all its products public. It’s a move that weaponizes transparency in a murky, trust-deficient industry.

Partillion Bioscience’s platform moves beyond single-cell analysis, letting researchers eavesdrop on cellular conversations to reshape drug discovery.

A new clinical trial for a sacroiliac joint device isn't just about technology; it's about a company's bet that rigorous evidence is the best medicine for patients and the healthcare system.

Sony's IMX711 isn't just a component; it's a strategic leap in industrial and scientific imaging, promising to break bottlenecks from battery lines to labs.

As Vivos Therapeutics pitches its revolutionary sleep apnea solution to investors, it's not just selling a device; it's fighting for its financial life.

With Bill S-228, Canada is criminalizing forced sterilization. It’s more than a new law; it’s a reckoning with a dark history and a test of reconciliation.

New research from Baycrest unmasks paratonia, an involuntary condition often mistaken as defiance, signaling a seismic shift in dementia care and treatment.

A German vitamin brand just hit 18M YouTube views. We analyze the audacious strategy to turn gummies into a global entertainment empire using AI.